SCHEMBL6284499

SCHEMBL6284499

COc1ccc(C2C(=O)c3ccc(OC)cc3C2=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.74
HPGD P15428 3/20 0.74
MAPT P10636 3/20 0.74
TP53 P04637 2/20 0.74
NPC1 O15118 1/20 0.74
MAOA P21397 1/20 0.74
PTGS2 P35354 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
GAA P10253 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
KMT2A Q03164 4/20 0.48
CYP2C9 P11712 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 3/20 0.47
CYP19A1 P11511 2/20 0.47
MAOB P27338 1/20 0.47
MEN1 O00255 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ACHE P22303 1/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anisindione SCHEMBL49379 0.85 RAB9A (1.00) RAB9AHPGDMAPTTP53NPC1
Anisindione SCHEMBL29688105 0.85 RAB9A (1.00) RAB9AHPGDMAPTTP53NPC1
SCHEMBL14939987 0.81 RAB9A (0.54) RAB9AHPGDMAPTTP53NPC1
SCHEMBL9790520 0.79 ACHE (0.54) RAB9AHPGDMAPTTP53NPC1
SCHEMBL6356064 0.79 RAB9A (0.59) RAB9AHPGDMAPTTP53NPC1
SCHEMBL19320919 0.78 MAPT (0.50) RAB9AHPGDMAPTTP53NPC1
SCHEMBL11808306 0.77 HPGD (0.45) RAB9AHPGDMAPTTP53NPC1
SCHEMBL11810507 0.76 RAB9A (0.47) RAB9AHPGDMAPTTP53NPC1
SCHEMBL14665734 0.75 MAOA (0.58) RAB9AHPGDMAPTTP53NPC1
SCHEMBL8958196 0.74 RAB9A (0.67) RAB9AHPGDMAPTTP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903238-B2 Substituted indenones as estrogenic agents WYETH (US) 2005-06-07 US disclosed
US-6838584-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2005-01-04 US disclosed
US-20040162304-A1 Estrogen receptor modulators MERCK & CO., INC. 2004-08-19 US disclosed
EP-1387821-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2004-02-11 EP disclosed
US-20030166643-A1 Substituted indenones as estrogenic agents WYETH 2003-09-04 US disclosed
WO-2002091993-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162304-A1 Estrogen receptor modulators ESRRA, GPER1, ESRRB RAB9A 3951/4885HPGD 784/4885MAPT 843/4885
US-20030166643-A1 Substituted indenones as estrogenic agents GPER1, ESR2, ESR1 RAB9A 3245/4885HPGD 1912/4885MAPT 3793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.